MG-K10 presented top-line data from its Phase II clinical trial for atopic dermatitis in a poster presentation at the 2024 American Academy of Dermatology Annual Meeting.
2024-03-11 0
On March 11, 2024, Mabgeek Bio announced that it would present its independently developed targeted IL- The top-line data of the Phase II study of MG-K10 humanized monoclonal antibody injection (hereinafter referred to as MG-K10), a Class 1 new drug targeting 4Rα.
Research background
•   ;MG-K10 is an innovative long-acting mAb that specifically binds to human IL-4Rα and effectively blocks Th2 inflammatory signaling of IL-4 and IL-13. MG-K10 has a long half-life , and intends to support long-interval dosing.
Research Methods
Research results
Conclusion
• Compared with the placebo group, all MG-K10 dose groups showed effective improvement in the treatment of moderate to severe AD; the 300mg Q4W group had the greatest improvement, and the primary efficacy endpoint and each secondary efficacy endpoint index at week 16 were significantly higher than those of the placebo group. There are significant differences.
• MG-K10 was safe and well tolerated.